Structural development studies of subtype-selective ligands for peroxisome proliferator-activated receptors (PPARs) based on the 3,4-disubstituted phenylpropanoic acid scaffold as a versatile template

Hiroyuki Miyachi, Yuichi Hashimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR) subtypes as pleiotropic regulators of biological responses, including lipid, lipoprotein, glucose homeostasis, inflammation, differentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPAR ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs, but also candidates for the treatment of PPAR-mediated diseases, including metabolic syndrome, inflammation, dementia, and cancer. This minireview summarizes our work on the design, synthesis, and pharmacological evaluation of subtype-selective PPAR agonists based on the use of 3,4-disubstituted phenylpropanoic acid as a versatile template.

Original languageEnglish
Article number689859
JournalPPAR Research
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Ligands
Acids
Inflammation
Metabolic Diseases
Cytoplasmic and Nuclear Receptors
Lipoproteins
Dementia
Neoplasms
Homeostasis
Pharmacology
Lipids
Glucose

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Drug Discovery

Cite this

@article{9ccdd09ff2824e37a261c7199b237174,
title = "Structural development studies of subtype-selective ligands for peroxisome proliferator-activated receptors (PPARs) based on the 3,4-disubstituted phenylpropanoic acid scaffold as a versatile template",
abstract = "Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR) subtypes as pleiotropic regulators of biological responses, including lipid, lipoprotein, glucose homeostasis, inflammation, differentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPAR ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs, but also candidates for the treatment of PPAR-mediated diseases, including metabolic syndrome, inflammation, dementia, and cancer. This minireview summarizes our work on the design, synthesis, and pharmacological evaluation of subtype-selective PPAR agonists based on the use of 3,4-disubstituted phenylpropanoic acid as a versatile template.",
author = "Hiroyuki Miyachi and Yuichi Hashimoto",
year = "2008",
doi = "10.1155/2008/689859",
language = "English",
journal = "PPAR Research",
issn = "1687-4757",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Structural development studies of subtype-selective ligands for peroxisome proliferator-activated receptors (PPARs) based on the 3,4-disubstituted phenylpropanoic acid scaffold as a versatile template

AU - Miyachi, Hiroyuki

AU - Hashimoto, Yuichi

PY - 2008

Y1 - 2008

N2 - Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR) subtypes as pleiotropic regulators of biological responses, including lipid, lipoprotein, glucose homeostasis, inflammation, differentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPAR ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs, but also candidates for the treatment of PPAR-mediated diseases, including metabolic syndrome, inflammation, dementia, and cancer. This minireview summarizes our work on the design, synthesis, and pharmacological evaluation of subtype-selective PPAR agonists based on the use of 3,4-disubstituted phenylpropanoic acid as a versatile template.

AB - Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR) subtypes as pleiotropic regulators of biological responses, including lipid, lipoprotein, glucose homeostasis, inflammation, differentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPAR ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs, but also candidates for the treatment of PPAR-mediated diseases, including metabolic syndrome, inflammation, dementia, and cancer. This minireview summarizes our work on the design, synthesis, and pharmacological evaluation of subtype-selective PPAR agonists based on the use of 3,4-disubstituted phenylpropanoic acid as a versatile template.

UR - http://www.scopus.com/inward/record.url?scp=47349085659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47349085659&partnerID=8YFLogxK

U2 - 10.1155/2008/689859

DO - 10.1155/2008/689859

M3 - Article

C2 - 18566690

AN - SCOPUS:47349085659

JO - PPAR Research

JF - PPAR Research

SN - 1687-4757

M1 - 689859

ER -